Explore new strategies for treating resistant lung cancer. Discover how blocking growth hormone receptors may improve ...
A Prescription Drug User Fee Act target date of July 27, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License ...
Ohio University researchers have discovered what may be a new way to fight lung cancer that is resistant to other treatments.
Somapacitan, a long-acting human growth hormone analog, was evaluated in growth hormone treatment-naïve, pre-pubertal pediatric patients.
Ascendis Pharma's supplemental application for SKYTROFA in adult GHD has been accepted by the FDA, aiming for broader patient access. Acceptance of the sBLA does not guarantee approval; the company ...
Human growth hormone (HGH) is a hormone that’s essential to our development. Most people produce enough HGH throughout their lifetime. But for those with a deficiency in growth hormone (or a few other ...
Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved three new indications for once-weekly Sogroya (R) (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg, a ...
From enhancing wound healing to combating neurodegeneration and cancer, growth hormone-releasing hormone and its analogs reveal groundbreaking roles that could redefine future therapies. Study: Growth ...
Acromegaly is a rare endocrine disorder characterised by the excessive secretion of growth hormone (GH), most frequently resulting from a benign pituitary adenoma. The consequent overproduction of ...
Dr. Jennifer Miller has been an author of dozens of studies about rare endocrine diseases over the last two decades. Hundreds of patients fly to Gainesville, Fla., from all over the U.S. to see her ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results